Literature DB >> 19040572

Regulation of apoptosis by type III interferons.

W Li1, A Lewis-Antes1, J Huang1, M Balan1, S V Kotenko1.   

Abstract

OBJECTIVE: Two types of interferons (IFNs), type I (IFN-alpha/beta) and type III (IFN-lambdas), utilize distinct receptor complexes to induce similar signalling and biological activities, including recently demonstrated for IFN-lambdas antitumour activity. However, ability of type III IFNs to regulate cell population growth remains largely uncharacterized.
MATERIALS AND METHODS: Intact and modified human colorectal adenocarcinoma HT29 cells were used to study regulation of apoptosis by IFN-lambdas. RESULTS AND
CONCLUSIONS: We report that the IFN-lambdaR1 chain of the type III IFN receptor complex possesses an intrinsic ability to trigger apoptosis in cells. Signalling induced through the intracellular domain of IFN-lambdaR1 resulted in G(1)/G(0) phase cell cycle arrest, phosphatidylserine surfacing and chromosomal DNA fragmentation. Caspase-3, caspase-8 and caspase-9 were activated; however, pancaspase inhibitor Z-VAD-FMK did not prevent apoptosis. In addition, the extent of apoptosis correlated with the level of receptor expression and was associated with prolonged IFN-lambda signalling. We also demonstrated that the ability to trigger apoptosis is a unique intrinsic function of all IFN receptors. However, more robust apoptosis was induced by signalling through type III IFN receptor than through type I or type II (IFN-gamma) receptors, suggesting higher cytotoxic potential of type III IFNs. In addition, we observed that IFN-gamma treatment sensitized HT29 cells to IFN-lambda-mediated apoptosis. These results provide evidence that type III IFNs, alone or in combination with other stimuli, have the potential to induce apoptosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19040572      PMCID: PMC6496378          DOI: 10.1111/j.1365-2184.2008.00558.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  76 in total

1.  Identification and functional characterization of a second chain of the interleukin-10 receptor complex.

Authors:  S V Kotenko; C D Krause; L S Izotova; B P Pollack; W Wu; S Pestka
Journal:  EMBO J       Date:  1997-10-01       Impact factor: 11.598

Review 2.  Phosphatidylserine recognition by phagocytes: a view to a kill.

Authors:  Yi Wu; Nitu Tibrewal; Raymond B Birge
Journal:  Trends Cell Biol       Date:  2006-03-10       Impact factor: 20.808

3.  IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.

Authors:  Sergei V Kotenko; Grant Gallagher; Vitaliy V Baurin; Anita Lewis-Antes; Meiling Shen; Nital K Shah; Jerome A Langer; Faruk Sheikh; Harold Dickensheets; Raymond P Donnelly
Journal:  Nat Immunol       Date:  2002-12-16       Impact factor: 25.606

Review 4.  Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators.

Authors:  Jean-Christophe Renauld
Journal:  Nat Rev Immunol       Date:  2003-08       Impact factor: 53.106

5.  Crystal structure of interleukin 10 reveals an interferon gamma-like fold.

Authors:  M R Walter; T L Nagabhushan
Journal:  Biochemistry       Date:  1995-09-26       Impact factor: 3.162

6.  Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. I. Cytotoxicity of interferon alpha in acute lymphoblastic leukemia.

Authors:  A Manabe; T Yi; M Kumagai; D Campana
Journal:  Leukemia       Date:  1993-12       Impact factor: 11.528

Review 7.  Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis.

Authors:  M Chawla-Sarkar; D J Lindner; Y-F Liu; B R Williams; G C Sen; R H Silverman; E C Borden
Journal:  Apoptosis       Date:  2003-06       Impact factor: 4.677

Review 8.  Interferon: cellular executioner or white knight?

Authors:  S G Maher; A L Romero-Weaver; A J Scarzello; A M Gamero
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

9.  Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3.

Authors:  D E Levy; D J Lew; T Decker; D S Kessler; J E Darnell
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

10.  Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus.

Authors:  Jiaying Huang; Sergey V Smirnov; Anita Lewis-Antes; Murugabaskar Balan; Wei Li; Sheila Tang; Gemma V Silke; Mike M Pütz; Geoffrey L Smith; Sergei V Kotenko
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-21       Impact factor: 11.205

View more
  40 in total

1.  Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection.

Authors:  Cristian Cilloniz; Mary J Pantin-Jackwood; Chester Ni; Alan G Goodman; Xinxia Peng; Sean C Proll; Victoria S Carter; Elizabeth R Rosenzweig; Kristy J Szretter; Jacqueline M Katz; Marcus J Korth; David E Swayne; Terrence M Tumpey; Michael G Katze
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFNλ signaling.

Authors:  Barbara Kroczynska; Sonali Joshi; Elizabeth A Eklund; Amit Verma; Sergei V Kotenko; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2010-11-12       Impact factor: 5.157

Review 3.  Investigations of interferon-lambda for the treatment of cancer.

Authors:  Andrew Stiff; William Carson
Journal:  J Innate Immun       Date:  2015-02-06       Impact factor: 7.349

4.  Kinetic Differences and Synergistic Antiviral Effects Between Type I and Type III Interferon Signaling Indicate Pathway Independence.

Authors:  Emily A Voigt; John Yin
Journal:  J Interferon Cytokine Res       Date:  2015-05-04       Impact factor: 2.607

5.  The DNA damage response induces IFN.

Authors:  Sabrina Brzostek-Racine; Chris Gordon; Sarah Van Scoy; Nancy C Reich
Journal:  J Immunol       Date:  2011-10-17       Impact factor: 5.422

6.  Interleukin-28B TT genotype is frequently found in patients with hepatitis C virus cirrhosis but does not influence hepatocarcinogenesis.

Authors:  Sara de la Fuente; María-Jesús Citores; Ana Duca; Elisa Cisneros; Isolina Baños; Carlos Vilches; Valentín Cuervas-Mons
Journal:  Clin Exp Med       Date:  2016-04-15       Impact factor: 3.984

7.  Recombinant adenovirus expressing hIFN-λ1 inhibits gastric adenocarcinoma cell line SGC-7901 proliferation.

Authors:  Xuefeng Bu; Mubin Wang; Jie Zhang; Jun Liu; Lijuan Jia; Bing Liang; Yulan Yan
Journal:  Oncol Lett       Date:  2015-11-06       Impact factor: 2.967

8.  Crystal structure of human interferon-λ1 in complex with its high-affinity receptor interferon-λR1.

Authors:  Zachary J Miknis; Eugenia Magracheva; Wei Li; Alexander Zdanov; Sergei V Kotenko; Alexander Wlodawer
Journal:  J Mol Biol       Date:  2010-10-08       Impact factor: 5.469

9.  IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.

Authors:  Masaya Sato; Naoya Kato; Ryosuke Tateishi; Ryosuke Muroyama; Norie Kowatari; Wenwen Li; Kaku Goto; Motoyuki Otsuka; Shuichiro Shiina; Haruhiko Yoshida; Masao Omata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2013-05-22       Impact factor: 7.527

10.  Type I interferon drives tumor necrosis factor-induced lethal shock.

Authors:  Liesbeth Huys; Filip Van Hauwermeiren; Lien Dejager; Eline Dejonckheere; Stefan Lienenklaus; Siegfried Weiss; Georges Leclercq; Claude Libert
Journal:  J Exp Med       Date:  2009-08-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.